Biologics manufacturing leader will highlight continued worldwide growth of operations to meet strong demand for vaccine and viral vector therapeutics, and pharmaceutical development and production. IDT to showcase Proveo™, with CMC Biologics, a much desired end-to-end solution for development and manufacture of Antibody Drug Conjugates with conjugation and fill-finish at one facility.
IDT Biologika, a globally integrated manufacturer of vaccines and biopharmaceuticals, will highlight its growing presence across the globe and expanded capabilities to supply world markets when it debuts its own booth at the 2016 BIO International Convention scheduled to take place June 6-9 at the Moscone Center in San Francisco. IDT Biologika will be located at Booth #5538 – South & North Halls.
“We are committed to continued expansion of our biologics manufacturing offerings to fulfill the growing needs of our customers in the global human and animal health marketplace,” said IDT Biologika CEO Dr. Ralf Pfirmann. “There is particularly strong demand for our expertise and manufacturing capacity for new vaccines. Additionally, we have formed a number of new global partnerships, such as our collaboration with CMC Biologics for ADC manufacturing, that are creating new and exciting opportunities for the pharma and biotech companies we serve. We are proud to showcase these capabilities at the upcoming BIO2016 as we extend our presence in North America.”
As a widely recognized, world-class vaccine manufacturer, IDT Biologika has invested significantly in developing manufacturing processes and systems for novel, innovative vaccines to address many globally relevant infectious diseases. Due to market demands, IDT Biologika continues to expand its infrastructure in the Dessau and the Riems, Germany and in Rockville, Maryland to better serve partners in the fast and efficient commercial manufacturing of drugs. In Dessau, an investment of € 50 million will increase the capacity of the high-speed filling line in operation since 2014. Following the opening of its state-of-the-art vaccine production facility in Rockville last year, IDT Biologika has upgraded the site’s production infrastructure for clinical Phase I and Phase II vaccine and viral vector projects.
In another move that will support operational growth and innovation, IDT Biologika has recently expanded its commitment to the development of antibody-drug conjugates (ADCs), a new class of therapeutic drugs intended to directly target cancer cells while minimizing systemic toxicity. Under its new strategic collaboration with CMC Biologics, IDT Biologika will showcase at the 2016 BIO International Convention its one-source offering that leverages the combined expertise, comprehensive services and multiple FDA-approved production sites of these two highly regarded contract manufacturing organizations. Proveo™ is a fully integrated, end-to-end solution for the production and manufacture of antibody drug conjugates (ADCs). It is designed to simplify the supply chain and shorten time to market, from DNA to commercial production of the finished ADC drug product – all according to the highest quality standards of national and international markets.
“Manufacturing an ADC is complex and challenging. We are confident that our combined upstream and downstream capabilities, credentials and expertise will allow us become the provider of choice for ADC developers in this important field of new highly effective cancer medications,” added Dr. Pfirmann.
IDT Biologika offers technically sophisticated development, manufacture and handling of vaccines, biopharmaceuticals and lyophilized compounds in EMA- and FDA-inspected facilities, and it has developed into one of the world’s leading pharmaceutical and biotechnological companies. In 2015, IDT Biologika achieved sales of approximately €202 million, an approximately 17 percent increase in business compared to the previous year.